IN THE CLAIMS:

1. (Currently Amended) An expandable intraluminal stent comprising:

a metal-main body portion having a metal surface wherein the surface

has a first end portion, a second end portion, and a middle portion having a surface, and;

a flow passage defined therethrough; and

wherein the first end portion has at least one surface having a biocompatible coating directly thereon on at least the first end portion of the metal surface of the main body portion, wherein the biocompatible coating comprises a polymer or a drug, and wherein the middle portion of the surface is free of the biocompatible coating.

- 2-49. (Canceled).
- 50. (Withdrawn) A method of manufacturing a stent comprising:

providing a main body portion having a first end portion, a second end portion, a middle portion having an outer surface and a flow passage defined therethrough, wherein the first end portion comprises an edge; and

forming a biocompatible coating directly on at least a portion of the edge, wherein the biocompatible coating comprises a polymer or a drug, and wherein the middle portion surface is free of the biocompatible coating.

- 51. (Withdrawn) The method of claim 50, wherein the entire edge of the first end portion has the biocompatible coating.
- 52. (Withdrawn) The method of claim 50, wherein the biocompatible coating comprises apertures or perforations.
- 53. (Withdrawn) The method of claim 50, wherein the biocompatible coating is formed by applying a plurality of layers comprising at least one coating material to form the biocompatible coating.
- 54. (Withdrawn) The method of claim 53, wherein the plurality of layers is comprised of the same coating material.
- 55. (Withdrawn) The method of claim 53, wherein the plurality of layers is comprised of different coating materials.
 - 56. (Withdrawn) The method of claim 50, wherein the polymer is a bioadhesive.

- 57. (Withdrawn) The method of claim 50, wherein the biocompatible coating comprises a polymer and a drug.
- 58. (Withdrawn) The method of claim 57, wherein the polymer comprises a gellike material.
- 59. (Withdrawn) The method of claim 57, wherein the drug is paclitaxel, an RGD peptide-containing compound, tranilast, trapidil, probucol, or a combination thereof.
- 60. (Withdrawn) The method of claim 50, wherein the first end portion is more flexible than the middle portion.
- 61. (Withdrawn) The method of claim 50, wherein the first end portion and middle portion are comprised of a mesh, and wherein the mesh of the first end portion is looser than the mesh of the middle portion.
- 62. (Withdrawn) The method of claim 50, further comprising treating the surface of the first end portion to form a smooth surface prior to forming the biocompatible coating directly thereon.
- 63. (Withdrawn) The method of claim 62, wherein the smooth surface is formed by electropolishing.
- 64. (Withdrawn) The method of claim 50, further comprising treating the first end portion to form a flexible first end portion prior to forming the biocompatible coating directly thereon. 16.
- 65. (Withdrawn) The method of claim 64, wherein the flexible first end portion is formed by heat-treating.
- 66. (Withdrawn) The method of claim 50, wherein the first end portion comprises a first metal and the middle portion comprises a second metal that is different from the first metal.
 - 67. (Withdrawn) A method of manufacturing a stent comprising:

providing a main body portion having a first end portion, a second end portion, a middle portion having an outer surface and a flow passage defined therethrough, wherein the first end portion comprises a first edge, and the second end portion comprises a second edge;

forming a first biocompatible coating directly on at least a portion of the first edge; and

forming a second biocompatible coating directly on at least a portion of the second edge, wherein the first biocompatible coating and the second biocompatible coating each comprise a polymer or a drug; and the middle portion surface is free of the first or second biocompatible coating.

- 68. (Withdrawn) The method of claim 67, wherein the first biocompatible coating is different than the second biocompatible coating.
 - 69. (Withdrawn) A method of manufacturing a stent comprising:

providing a main body portion having a first end portion, a second end portion, a middle portion having an outer surface, and a flow passage defined therethrough, wherein the first end portion comprises an edge; and

applying a sleeve directly on at least a portion of the edge, wherein the sleeve comprises at least one layer of a material comprising a bioadhesive, a drug, or a combination thereof, and wherein the middle portion surface is free of the layer of material.

70. (Withdrawn) A method of manufacturing a stent of claim 1 comprising:

providing a main body portion having a first end portion, a second end portion, a middle portion having an outer surface and a flow passage defined therethrough, wherein the first end portion comprises an edge; and

forming a biocompatible coating directly on at least a portion of the edge, wherein the biocompatible coating comprises a polymer or a drug, and wherein the middle portion surface is free of the biocompatible coating.

- 71. (Withdrawn) The method of claim 70, wherein the entire edge of the first end portion has the biocompatible coating.
- 72. (Withdrawn) The method of claim 70, wherein the biocompatible coating comprises apertures or perforations.
- 73. (Withdrawn) The method of claim 70, wherein the biocompatible coating is formed by applying a plurality of layers comprising at least one coating material to form the biocompatible coating.
- 74. (Withdrawn) The method of claim 73, wherein the plurality of layers is comprised of the same coating material.

- 75. (Withdrawn) The method of claim 73, wherein the plurality of layers is comprised of different coating materials.
 - 76. (Withdrawn) The method of claim 70, wherein the polymer is a bioadhesive.
- 77. (Withdrawn) The method of claim 70, wherein the biocompatible coating comprises a polymer and a drug.
- 78. (Withdrawn) The method of claim 77, wherein the polymer comprises a gellike material.
- 79. (Withdrawn) The method of claim 77, wherein the drug is paclitaxel, an RGD peptide-containing compound, tranilast, trapidil, probucol, or a combination thereof.
- 80. (Withdrawn) The method of claim 70, wherein the first end portion is more flexible than the middle portion.
- 81. (Withdrawn) The method of claim 70, wherein the first end portion and middle portion are comprised of a mesh, and wherein the mesh of the first end portion is looser than the mesh of the middle portion.
- 82. (Withdrawn) The method of claim 70, further comprising treating the surface of the first end portion to form a smooth surface prior to forming the biocompatible coating directly thereon.
- 83. (Withdrawn) The method of claim 72, wherein the smooth surface is formed by electropolishing.
- 84. (Withdrawn) The method of claim 70, further comprising treating the first end portion to form a flexible first end portion prior to forming the biocompatible coating directly thereon.
- 85. (Withdrawn) The method of claim 74, wherein the flexible first end portion is formed by heat-treating.
- 86. (Withdrawn) The method of claim 70, wherein the first end portion comprises a first metal and the middle portion comprises a second metal that is different from the first metal.
 - 87. (Withdrawn) A method of manufacturing the stent of claim 1 comprising:

providing a main body portion having a first end portion, a second end portion, a middle portion having an outer surface and a flow passage defined therethrough, wherein the first end portion comprises a first edge, and the second end portion comprises a second edge;

forming a first biocompatible coating directly on at least a portion of the first edge; and

forming a second biocompatible coating directly on at least a portion of the second edge, wherein the first biocompatible coating and the second biocompatible coating each comprise a polymer or a drug; and the middle portion surface is free of the first or second biocompatible coating.

- 88. (Withdrawn) The method of claim 87, wherein the first biocompatible coating is different than the second biocompatible coating.
- 89. (Withdrawn) A method of manufacturing the stent of claim 1 comprising:

 providing a main body portion having a first end portion, a second end
 portion, a middle portion having an outer surface, and a flow passage defined therethrough,
 wherein the first end portion comprises an edge; and

applying a sleeve directly on at least a portion of the edge, wherein the sleeve comprises at least one layer of a material comprising a bioadhesive, a drug, or a combination thereof, and wherein the middle portion surface is free of the layer of material.

- 90. (Cancelled).
- 91. (Previously Presented) The stent of claim 1, wherein the biocompatible coating comprises apertures or perforations.
- 92. (Previously Presented) The stent of claim 1, wherein the biocompatible coating comprises a plurality of layers comprising at least one coating material.
- 93. (Previously Presented) The stent of claim 92, wherein the plurality of layers comprises the same coating material.
- 94. (Previously Presented) The stent of claim 92, wherein the plurality of layers comprises different coating materials.
- 95. (Previously Presented) The stent of claim 1, wherein the polymer is a bioadhesive.

- 96. (Previously Presented) The stent of claim 1, wherein the polymer comprises a gel-like material.
- 97. (Previously Presented) The stent of claim 1, wherein the drug is paclitaxel, an RGD peptide-containing compound, tranilast, trapidil, probucol, or a combination thereof.
- 98. (Currently Amended) The stent of claim 1, wherein the main body portion has a first end portion, a middle portion and a second end portion, and wherein the first end portion of the main body portion is more flexible than the middle portion of the main body portion.
- 99. (Currently Amended) The stent of claim 1, wherein the main body portion has a first end portion, a middle portion and a second end portion, and wherein the first end portion of the main body portion and middle portion of the main body portion are comprised of a mesh, and wherein the mesh of the first end portion is looser than the mesh of the middle portion.
- 100. (Previously Presented) The stent of claim 1, wherein the stent is balloon-expandable.
- 101. (Previously Presented) The stent of claim 1, wherein the metal comprises stainless steel.